Results 21 to 30 of about 370,832 (346)

Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine

open access: yesOpen Life Sciences, 2022
In influenza vaccine development, Madin–Darby canine kidney (MDCK) cells provide multiple advantages, including large-scale production and egg independence. Several cell-based influenza vaccines have been approved worldwide.
Zhang Zhegang   +19 more
doaj   +1 more source

Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use

open access: yesViruses, 2022
The COVID-19 pandemic has highlighted the need for efficient vaccine platforms that can rapidly be developed and manufactured on a large scale to immunize the population against emerging viruses.
Julia P. C. Fulber, Amine A. Kamen
doaj   +1 more source

Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation

open access: yesVaccines, 2020
Vaccine design strategies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are focused on the Spike protein or its subunits as the main antigen target of neutralizing antibodies. In this work, we propose rapid production methods of an
Omar Farnós   +10 more
doaj   +1 more source

Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future [PDF]

open access: yes, 2014
Serological techniques commonly used to quantify influenza-specific antibodies include the Haemagglutination Inhibition (HI), Single Radial Haemolysis (SRH) and Virus Neutralization (VN) assays.
Callow   +30 more
core   +3 more sources

Chemical-free inactivated whole influenza virus vaccine prepared by ultrashort pulsed laser treatment [PDF]

open access: yes, 2014
There is an urgent need for rapid methods to develop vaccines in response to emerging viral pathogens. Whole inactivated virus (WIV) vaccines represent an ideal strategy for this purpose; however, a universal method for producing safe and immunogenic ...
Achilefu, Samuel   +10 more
core   +2 more sources

Roadblocks to translational challenges on viral pathogenesis. [PDF]

open access: yes, 2013
Distinct roadblocks prevent translating basic findings in viral pathogenesis into therapies and implementing potential solutions in the clinic. An ongoing partnership between the Volkswagen Foundation and Nature Medicine resulted in an interactive ...
Deeks, Steven   +4 more
core   +1 more source

New viral vaccines

open access: yesVirology, 2006
Vaccination is the most effective medical intervention against diseases caused by human viral pathogens. Viral vaccines prevent or modify the severity of illness in the individual and interrupt or reduce the transmission of the pathogens to other susceptible people.
Arvin, Ann M., Greenberg, Harry B.
openaire   +2 more sources

A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus [PDF]

open access: yes, 2014
Bluetongue is one of the major infectious diseases of ruminants and is caused by Bluetongue virus (BTV), an arbovirus existing in nature in at least 26 distinct serotypes. Here, we describe the development of a vaccine platform for BTV.
Brunet, Silvie   +6 more
core   +2 more sources

Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas. [PDF]

open access: yes, 2019
Congenital human cytomegalovirus (HCMV) infection is a leading cause of birth defects worldwide, yet the most effective strategies for preventing virus transmission during pregnancy are unknown.
An, Zhiqiang   +8 more
core   +1 more source

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. [PDF]

open access: yes, 2015
The polio eradication endgame aims to bring transmission of all polioviruses to a halt. To achieve this aim, it is essential to block viral replication in individuals via induction of a robust mucosal immune response. Although it has long been recognized
Anis E   +16 more
core   +3 more sources

Home - About - Disclaimer - Privacy